CSTL: Q2 2026 revenues up 20% YoY to $103.5M, driven by TissueCypher growth; net loss $2.1M
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenues rose 20% year-over-year to $103.5M, led by strong TissueCypher growth, while dermatologic test revenues declined due to Medicare coverage loss for DecisionDx-SCC. Gross margin remained strong at 74.9%, but net loss was $2.1M as operating expenses increased. Liquidity remains solid, with $62.1M in cash and $204.7M in securities.Original document: Castle Biosciences, Inc. [CSTL] SEC 10-Q Quarterly Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenues rose 20% year-over-year to $103.5M, led by strong TissueCypher growth, while dermatologic test revenues declined due to Medicare coverage loss for DecisionDx-SCC. Gross margin remained strong at 74.9%, but net loss was $2.1M as operating expenses increased. Liquidity remains solid, with $62.1M in cash and $204.7M in securities.
Original document: Castle Biosciences, Inc. [CSTL] SEC 10-Q Quarterly Report — Jul. 30 2026